Immunotherapy with Pembrolizumab in Metastatic Prostate Cancer: Highlights in GU Oncology from ASCO 2018 (BMIC-055)

Dr. Daniel Goldstein summarizes key data in genitourinary oncology from ASCO 2018, including new results on pembrolizumab (Keytruda) for metastatic prostate cancer, asking whether it could find a plac... Author: BeaconMedIC Added: 08/16/2018
Source: Oncology Tube - Category: Cancer & Oncology Source Type: podcasts